NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection

Overview

Journal J Natl Compr Canc Netw

Specialty Oncology

Date 2018 May 23

PMID 29784740

Citations 123

Authors

Peter H Carroll

James L Mohler

Affiliations

Soon will be listed here.

Abstract

Peter H. Carroll, MD, MPH, and James L. Mohler, MD, updated attendees on what is new in the 2018 NCCN Guidelines for Prostate Cancer Early Detection and for Prostate Cancer, respectively. Their presentations touched on new screening recommendations, shared decision-making, risk stratification, the role of genomic and molecular testing, active surveillance, and newer systemic treatments.

Citing Articles

Development of a deep learning system for predicting biochemical recurrence in prostate cancer.

Cao L, He R, Zhang A, Li L, Cao W, Liu N BMC Cancer. 2025; 25(1):232.

PMID: 39930342 PMC: 11812243. DOI: 10.1186/s12885-025-13628-9.

Ascertaining provider-level implicit bias in electronic health records with rules-based natural language processing: A pilot study in the case of prostate cancer.

Ramaswamy A, Hung M, Pelt J, Iranmahboub P, Calderon L, Scherr I PLoS One. 2025; 19(12):e0314989.

PMID: 39775249 PMC: 11684669. DOI: 10.1371/journal.pone.0314989.

Developments in radionanotheranostic strategies for precision diagnosis and treatment of prostate cancer.

Andrew J, Ezra-Manicum A, Witika B EJNMMI Radiopharm Chem. 2024; 9(1):62.

PMID: 39180599 PMC: 11344754. DOI: 10.1186/s41181-024-00295-7.

How Agent Orange impacts prostate cancer risk, pathology, and treatment outcomes.

Paracha A, Siddiqui Z, Abid A, Deol E, Waheed F, Hamilton Z Curr Urol. 2024; 18(2):79-86.

PMID: 39176301 PMC: 11337987. DOI: 10.1097/CU9.0000000000000244.

Integrating Whole-Slide Imaging and MRI Data for Outcome Prediction after Prostatectomy in Localized Prostate Cancer.

Harmon S, Turkbey B Radiol Imaging Cancer. 2024; 6(3):e240095.

PMID: 38787304 PMC: 11148823. DOI: 10.1148/rycan.240095.